Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Poster Session

Sjögren’s Disease

Poster Session C

Session: (2290–2304) Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures

2292: Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren's Disease Patients: Results From a Double-Blinded Placebo-Controlled Study

Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Location: Hall F1
Table. Humoral response rates 6 weeks after the 2nd RZV dose and anti-gE IgG titers before (D0) and after two doses in patients with SjD and CG

CG – control group, SjD – Sjögren’s disease. RZV – recombinant herpes zoster vaccine, GMT – geometric mean titers (mIU/mL).
Frequencies of humoral response are presented as number (%) and they were compared using two-sided chi-square test between SjD and CG at 6 weeks after the 2nd RZV dose.
Anti-gE IgG titers and factor increase (FI) in GMT are expressed as geometric means with 95% confidence interval (95%CI).
Data regarding anti-gE titers were analyzed using ANOVA with repeated measures and 2 factors [2 groups (SjD vs. CG), at 2 time points (D0 and 6 weeks after the 2nd RZV dose)], followed by Bonferroni’s multiple comparisons at neperian logarithm (ln)-transformed data. GMT and FI-GMT were compared using Mann-Whitney test for intergroup comparisons in ln-transformed data at pre-specified time points (D0 and 6 weeks after de 2nd dose). All analyses were two-sided.
P1 – SjD patients who received the RZV on the day of randomization (D0) and after 6 weeks (D42).
P2 – SjD patients who initially received placebo and were vaccinated 12 weeks after randomization, on D84 and after 6 weeks (D126).

    Abstract Poster Presenter(s)

  • AM

    Ana Medeiros-Ribeiro, MD, PhD (she/her/hers)

    Hospital das Clinicas da Faculdade de Medicina da USP
    Sao Paulo, São Paulo, Brazil

    Disclosure(s): GlaxoSmithKlein(GSK): Grant/Research Support (Ongoing)


Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant HZ vaccine (RZV, Shingrix®) in these patients remain limited. Concerns about disease flares following vaccine, as highlighted in studies of COVID-19 vaccination, further underscore the need for target evaluation. Purpose: To evaluate the safety and immunogenicity of RZV in immunosuppressed SjD.

Methods: In this randomized, double-blind, placebo-controlled trial, 67 adults immunosuppressed SjD patients (excluding rituximab) were enrolled, alongside 201 non-immunosuppressed control individuals (CG). SjD patients were randomized to receive vaccine (P1) or placebo (P2) at day 0 (D0) and D42, with placebo recipients vaccinated after unblinding (D84 and D126). CG were immunized at D0 and D42. Disease activity [ESSDAI (European League Against Rheumatism-EULAR Sjögren's Syndrome Disease Activity Index)] and adverse events (AEs) were monitored at all visits. Humoral immunogenicity was assessed by serum anti-gE antibody concentrations using a GSK ELISA. The humoral response to VZR was defined as anti-gE concentration ≥4-fold the pre-vaccination concentration. Geometric Mean Titer (GMT) and Factor Increase (FI-GMT) were calculated.

Results: Vaccine (P1) and placebo (P2) groups were comparable in terms of age (p=0.5), sex (p=1.0), prednisone use (p=0.3) and dosage (0.6), as well as treatment with hydroxychloroquine (p=0.7), methotrexate (p=0.5), leflunomide (p=0.4), azathioprine (p=0.5), and mycophenolate mofetil (p=0.8). Baseline disease activity, assessed by ESSDAI, was similar between P1 and P2 [2.0 (0.0-2.0) vs. 1.0 (0.0-2.5), p=0.7], and most patients presented low disease activity (ESSDAI < 5) in both groups (87.1% vs. 88.9%, p=1.0), respectively. No significant changes in ESSDAI were observed six weeks after the 1st (p=0.5) or 2nd (p=0.2) RZV dose. Flare rates, defined as increase ≥3 points in ESSDAI and/or increased glucocorticoid/immunosuppressant therapy, were also comparable between groups throughout the study (p >0.05). Regarding AEs, after the 1st RZV dose, local reactions were less frequent among SjD than in CG (70.1% vs. 84.6%, p=0.009), as were systemic reactions (50.7% vs. 62.2%, p=0.1). After the 2nd RZV dose, the rates were comparable between groups (p >0.05). No serious AEs were observed. Analysis of immunogenicity comparing SjD and age [55.0 (48.3-63.8) vs. 55.0 (52.0-64.0) years, p=0.1] and sex (female: 95.5% vs. 90.5%, p=0.3, respectively) balanced CG revealed a reduced humoral response in SjD patients (90.6% vs. 99.5%, p=0.0009). Furthermore, GMT and FI-GMT were significantly lower in SjD patients compared to controls (Table).

Conclusion: RZV demonstrated an excellent safety profile in immunosuppressed SjD patients, without triggering significant disease flares. Although the vaccine induced a high rate of humoral response, the magnitude of the response was significantly lower compared to healthy controls, which may have implications for long-term protection. (ClinicalTrials NCT05879419).